FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma By Ogkologos - March 27, 2025 519 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ECHELON-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance MOST POPULAR Stimulating the Immune System Shrinks Some Slow-Growing Lymphomas September 26, 2018 Rookie Cop Saves Infant From Choking October 24, 2021 Unusual or Nonreportable Results from Prenatal cfDNA-Sequencing Suggestive for an Occult... December 13, 2024 Study Examines Whether Blood Test Can Identify Early Cancers June 2, 2020 Load more HOT NEWS KRASG12 Mutations Are Biomarkers for Reduced Overall Survival Benefit of Treatment... Adding Upfront SRS to CNS-penetrant TKI Improves Time-to-CNS Progression and Local... Professor Ian Tomlinson: “Philanthropy is priceless to science” Utility of a Methylation-Based Multicancer Early Detection Test in Identifying Whom...
